Do analysts rate OPTX or LAB?

Standard BioTools has a consensus target price of $1.35, suggesting a potential upside of 80.63%. Given Standard BioTools' stronger consensus rating and higher probable upside, analysts clearly believe Standard BioTools is more favorable than Syntec Optics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syntec Optics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Standard BioTools 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Standard BioTools (LAB) Competitors

$0.75 +0.01 (+1.80%)

Closing price 06/29/2026 04:00 PM Eastern

Extended Trading

$0.74 -0.01 (-1.12%)

As of 04:12 AM Eastern

Compare

LAB vs. EYPT, TRNS, FEIM, CTKB, and OPTX

Should you buy Standard BioTools stock or one of its competitors? MarketBeat compares Standard BioTools with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Standard BioTools include Eyepoint Pharmaceuticals (EYPT), Transcat (TRNS), Frequency Electronics (FEIM), Cytek Biosciences (CTKB), and Syntec Optics (OPTX). These companies are all part of the "measuring and control equipment" industry.

How does Standard BioTools compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Standard BioTools has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	37.71	-$231.96M	-$3.50	N/A
Standard BioTools	$85.33M	3.42	-$74.90M	$0.20	3.74

Eyepoint Pharmaceuticals presently has a consensus target price of $37.83, indicating a potential upside of 168.13%. Standard BioTools has a consensus target price of $1.35, indicating a potential upside of 80.63%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Eyepoint Pharmaceuticals has a beta of 1.72, meaning that its share price is 72% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market.

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by insiders. Comparatively, 26.8% of Standard BioTools shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Eyepoint Pharmaceuticals had 1 more articles in the media than Standard BioTools. MarketBeat recorded 2 mentions for Eyepoint Pharmaceuticals and 1 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.87 beat Eyepoint Pharmaceuticals' score of 0.94 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Overall Sentiment
Eyepoint Pharmaceuticals	Positive
Standard BioTools	Very Positive

Standard BioTools has a net margin of 73.46% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Standard BioTools' return on equity of -8.18% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
Standard BioTools	73.46%	-8.18%	-6.43%

Summary

Standard BioTools beats Eyepoint Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Standard BioTools compare to Transcat?

Transcat (NASDAQ:TRNS) and Standard BioTools (NASDAQ:LAB) are both small-cap measuring and control equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Standard BioTools has a net margin of 73.46% compared to Transcat's net margin of 1.62%. Transcat's return on equity of 5.84% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Transcat	1.62%	5.84%	3.78%
Standard BioTools	73.46%	-8.18%	-6.43%

Transcat currently has a consensus price target of $105.33, indicating a potential upside of 15.40%. Standard BioTools has a consensus price target of $1.35, indicating a potential upside of 80.63%. Given Standard BioTools' higher probable upside, analysts clearly believe Standard BioTools is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

98.3% of Transcat shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 2.8% of Transcat shares are owned by company insiders. Comparatively, 26.8% of Standard BioTools shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Transcat has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

Transcat has higher revenue and earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Transcat	$331.88M	2.57	$5.38M	$0.58	157.38
Standard BioTools	$85.33M	3.42	-$74.90M	$0.20	3.74

In the previous week, Transcat had 4 more articles in the media than Standard BioTools. MarketBeat recorded 5 mentions for Transcat and 1 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.87 beat Transcat's score of 0.75 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Overall Sentiment
Transcat	Positive
Standard BioTools	Very Positive

Summary

Transcat beats Standard BioTools on 11 of the 17 factors compared between the two stocks.

How does Standard BioTools compare to Frequency Electronics?

Standard BioTools (NASDAQ:LAB) and Frequency Electronics (NASDAQ:FEIM) are both small-cap measuring and control equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 58.6% of Frequency Electronics shares are owned by institutional investors. 26.8% of Standard BioTools shares are owned by insiders. Comparatively, 28.0% of Frequency Electronics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Frequency Electronics has lower revenue, but higher earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than Frequency Electronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	3.42	-$74.90M	$0.20	3.74
Frequency Electronics	$69.81M	8.71	$23.69M	$0.75	82.36

In the previous week, Standard BioTools and Standard BioTools both had 1 articles in the media. Frequency Electronics' average media sentiment score of 1.89 beat Standard BioTools' score of 1.87 indicating that Frequency Electronics is being referred to more favorably in the news media.

Company	Overall Sentiment
Standard BioTools	Very Positive
Frequency Electronics	Very Positive

Standard BioTools has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, Frequency Electronics has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Standard BioTools presently has a consensus price target of $1.35, indicating a potential upside of 80.63%. Frequency Electronics has a consensus price target of $43.67, indicating a potential downside of 29.31%. Given Standard BioTools' higher probable upside, equities analysts plainly believe Standard BioTools is more favorable than Frequency Electronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

Standard BioTools has a net margin of 73.46% compared to Frequency Electronics' net margin of 10.78%. Frequency Electronics' return on equity of 12.69% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	73.46%	-8.18%	-6.43%
Frequency Electronics	10.78%	12.69%	7.84%

Summary

Frequency Electronics beats Standard BioTools on 12 of the 16 factors compared between the two stocks.

How does Standard BioTools compare to Cytek Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Standard BioTools has a net margin of 73.46% compared to Cytek Biosciences' net margin of -36.25%. Standard BioTools' return on equity of -8.18% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-36.25%	-10.07%	-7.56%
Standard BioTools	73.46%	-8.18%	-6.43%

69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 10.4% of Cytek Biosciences shares are held by company insiders. Comparatively, 26.8% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cytek Biosciences has higher revenue and earnings than Standard BioTools. Cytek Biosciences is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	2.78	-$66.54M	-$0.57	N/A
Standard BioTools	$85.33M	3.42	-$74.90M	$0.20	3.74

Cytek Biosciences has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

In the previous week, Cytek Biosciences had 1 more articles in the media than Standard BioTools. MarketBeat recorded 2 mentions for Cytek Biosciences and 1 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.87 beat Cytek Biosciences' score of 1.23 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Overall Sentiment
Cytek Biosciences	Positive
Standard BioTools	Very Positive

Cytek Biosciences presently has a consensus price target of $5.69, suggesting a potential upside of 31.05%. Standard BioTools has a consensus price target of $1.35, suggesting a potential upside of 80.63%. Given Standard BioTools' higher probable upside, analysts clearly believe Standard BioTools is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Standard BioTools beats Cytek Biosciences on 10 of the 16 factors compared between the two stocks.

How does Standard BioTools compare to Syntec Optics?

Syntec Optics (NASDAQ:OPTX) and Standard BioTools (NASDAQ:LAB) are both small-cap measuring and control equipment companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Standard BioTools has a consensus target price of $1.35, suggesting a potential upside of 80.63%. Given Standard BioTools' stronger consensus rating and higher probable upside, analysts clearly believe Standard BioTools is more favorable than Syntec Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syntec Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Syntec Optics has higher earnings, but lower revenue than Standard BioTools. Syntec Optics is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syntec Optics	$27.53M	15.48	-$1.79M	-$0.08	N/A
Standard BioTools	$85.33M	3.42	-$74.90M	$0.20	3.74

In the previous week, Syntec Optics had 2 more articles in the media than Standard BioTools. MarketBeat recorded 3 mentions for Syntec Optics and 1 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.87 beat Syntec Optics' score of 0.90 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Overall Sentiment
Syntec Optics	Positive
Standard BioTools	Very Positive

53.7% of Standard BioTools shares are held by institutional investors. 0.8% of Syntec Optics shares are held by insiders. Comparatively, 26.8% of Standard BioTools shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Syntec Optics has a beta of -0.82, meaning that its share price is 182% less volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market.

Standard BioTools has a net margin of 73.46% compared to Syntec Optics' net margin of -10.95%. Standard BioTools' return on equity of -8.18% beat Syntec Optics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syntec Optics	-10.95%	-30.86%	-12.35%
Standard BioTools	73.46%	-8.18%	-6.43%

Summary

Standard BioTools beats Syntec Optics on 12 of the 15 factors compared between the two stocks.

Get Standard BioTools News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LAB vs. The Competition

Export

Metric	Standard BioTools	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$286.61M	$1.71B	$6.84B	$12.20B
Dividend Yield	N/A	N/A	2.66%	6.22%
P/E Ratio	3.74	79.80	26.04	24.37
Price / Sales	3.42	7.65	547.53	100.48
Price / Cash	N/A	24.73	29.09	36.93
Price / Book	0.68	5.63	10.97	6.49
Net Income	-$74.90M	-$54.76M	$3.57B	$336.61M
7 Day Performance	-5.64%	3.51%	2.50%	1.20%
1 Month Performance	-35.01%	-1.75%	0.86%	0.20%
1 Year Performance	-37.72%	1.45%	36.40%	30.15%

Standard BioTools Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LAB Standard BioTools	3.9987 of 5 stars	$0.75 +1.8%	$1.35 +80.6%	-37.2%	$286.61M	$85.33M	3.74	620	Positive News Gap Up
EYPT Eyepoint Pharmaceuticals	2.9182 of 5 stars	$14.11 +2.8%	$31.80 +125.3%	+46.4%	$1.18B	$31.37M	N/A	120
TRNS Transcat	3.3342 of 5 stars	$91.62 -1.2%	$105.33 +15.0%	+7.6%	$853.21M	$331.88M	157.49	1,413	Analyst Upgrade
FEIM Frequency Electronics	1.2903 of 5 stars	$69.39 -0.5%	$43.67 -37.1%	+165.3%	$682.80M	$69.81M	92.52	200	Positive News
CTKB Cytek Biosciences	2.7958 of 5 stars	$4.07 +5.3%	$5.69 +39.9%	+22.3%	$524.18M	$201.49M	N/A	500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LAB) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Standard BioTools (LAB) Competitors

LAB vs. EYPT, TRNS, FEIM, CTKB, and OPTX

How does Standard BioTools compare to Eyepoint Pharmaceuticals?

Summary

How does Standard BioTools compare to Transcat?

Summary

How does Standard BioTools compare to Frequency Electronics?

Summary

How does Standard BioTools compare to Cytek Biosciences?

Summary

How does Standard BioTools compare to Syntec Optics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LAB vs. The Competition

Standard BioTools Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Standard BioTools (LAB) Competitors

LAB vs. EYPT, TRNS, FEIM, CTKB, and OPTX

How does Standard BioTools compare to Eyepoint Pharmaceuticals?

Which has better valuation & earnings, EYPT or LAB?

Do analysts prefer EYPT or LAB?

Which has more volatility & risk, EYPT or LAB?

Do institutionals & insiders believe in EYPT or LAB?

Does the media prefer EYPT or LAB?

Is EYPT or LAB more profitable?

Summary

How does Standard BioTools compare to Transcat?

Is TRNS or LAB more profitable?

Do analysts recommend TRNS or LAB?

Do insiders & institutionals believe in TRNS or LAB?

Which has more volatility & risk, TRNS or LAB?

Which has better earnings & valuation, TRNS or LAB?

Does the media prefer TRNS or LAB?

Summary

How does Standard BioTools compare to Frequency Electronics?

Do institutionals & insiders believe in LAB or FEIM?

Which has better valuation and earnings, LAB or FEIM?

Does the media favor LAB or FEIM?

Which has more volatility and risk, LAB or FEIM?

Do analysts recommend LAB or FEIM?

Is LAB or FEIM more profitable?

Summary

How does Standard BioTools compare to Cytek Biosciences?

Is CTKB or LAB more profitable?

Do insiders and institutionals have more ownership in CTKB or LAB?

Which has better earnings and valuation, CTKB or LAB?

Which has more risk and volatility, CTKB or LAB?

Does the media prefer CTKB or LAB?

Do analysts recommend CTKB or LAB?

Summary

How does Standard BioTools compare to Syntec Optics?

Do analysts rate OPTX or LAB?

Which has higher valuation & earnings, OPTX or LAB?

Does the media prefer OPTX or LAB?

Do institutionals & insiders have more ownership in OPTX or LAB?

Which has more volatility & risk, OPTX or LAB?

Is OPTX or LAB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LAB vs. The Competition

Standard BioTools Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools